Genetic detection isn’t always clinical truth: why phenotypic AMR testing still matters

In the hospital microbiology lab, a blood culture has just turned positive. In the emergency department, a patient with suspected sepsis has deteriorated rapidly. Earlier in the evening, they appeared unwell but stable. Now they are confused and critically ill. Broad-spectrum antibiotics have been started, but the clinical team is waiting for results that could guide treatment. Every hour without effective therapy increases risk. 

In this moment, speed matters – but speed alone is not enough. Clinicians don’t just need information quickly; they need to know it can be trusted. 

Rapid molecular diagnostics can provide early insight, identifying pathogens and screening for known resistance genes within hours. That information is valuable. It can inform initial decisions and narrow possibilities. 

But it does not resolve the core clinical question: will this infection respond to the treatment being given? Genetic detection describes potential. It does not confirm what happens when pathogen meets antibiotic.

Genes signal potential, growth reveals reality

Molecular panels only detect what they are designed to find. PCR-based methods can also identify genetic material regardless of whether the organism is viable. 

This is why phenotypic testing remains essential. It measures what actually happens when bacteria are exposed to antibiotics: whether growth continues, slows, or is inhibited. It reflects biological reality, not inferred risk. 

Historically, the challenge has been speed. Phenotypic methods deliver trusted, clinically relevant results, but often too late to influence early treatment decisions. This has created a long-standing compromise: rapid but indirect genotypic insight, or slower but definitive phenotypic data. 

Rapid phenotypic AST: closing the gap

A new generation of rapid phenotypic antibiotic susceptibility testing (AST) is now addressing this challenge. These technologies retain the core strength of phenotype by measuring real microbial behaviour under antibiotic exposure, while delivering results within clinically actionable timeframes. 

In bloodstream infections, susceptibility data can now be generated within 4 – 8 hours. In near-patient applications such as urinary tract infections (UTIs), results can be available in as little as 30 – 45 minutes. This shifts phenotypic testing from retrospective confirmation to real-time decision support. 

The field is moving quickly from innovation to adoption. Recognition through initiatives such as the Longitude Prize on AMR, awarded to Sysmex Astrego, reflects this shift. Rapid phenotypic AST is no longer emerging; it’s becoming central to the future of infectious disease management. 

For the patient in the emergency department, this difference is critical. A result delivered within the same shift can still change the course of treatment. 

Different technologies, one objective

A range of technologies are driving this progress, but they share a common goal: reaching biological truth faster. 

Microfluidics miniaturises testing environments, accelerating bacterial response under controlled conditions. Imaging and single-cell analysis detect early behavioural changes before visible growth. Alternative sensing methods, including fluorescence, Raman spectroscopy, and electrical signals, capture early metabolic or physical responses. 

Different approaches, but a single endpoint: understanding what happens when pathogen meets antibiotic. This is where CPI plays a critical role. Working with partners across diagnostics, industry, and healthcare, CPI supports the translation of rapid phenotypic AST from promising innovation into deployable solutions. By combining expertise in biology, engineering, and system design, CPI helps ensure technologies are not only scientifically robust, but also scalable, reliable, and ready for clinical use. 

From innovation to implementation: the real challenge

Delivering impact in this space requires more than speed. Systems must be designed for real-world use, addressing sample preparation, contamination control, organism variability, antibiotic panel design, workflow integration, turnaround time, manufacturability, and cost. 

Success depends as much on engineering and usability as on biology. The technologies that succeed will not simply measure faster but translate phenotypic insight into systems that laboratories and clinicians can adopt with confidence. 

In central laboratories, direct-from-positive-blood-culture systems are demonstrating that same-shift susceptibility testing is achievable. At the same time, near-patient platforms such as Sysmex Astrego are bringing phenotypic testing closer to the point of prescribing, particularly for UTIs. 

Underpinning both is a growing technology base, spanning microfluidics, imaging, electrical sensing, and Raman approaches, all focused on delivering actionable, biology-driven insights at the point of need. 

The real opportunity: from empiric to targeted treatment

The next step is applying these advances to areas of greatest unmet need, including sepsis, complicated UTIs, hospital-acquired infections, and resistant Gram-negative disease – settings where broad empiric therapy still dominates because actionable data arrives too late. 

Rapid phenotypic AST has the potential to move clinicians more quickly from educated guesswork to targeted treatment. It can shorten the gap between empiric therapy and optimisation, reduce unnecessary use of broad-spectrum antibiotics, and support more confident prescribing decisions. 

This shift matters not only for individual patients but for antimicrobial stewardship and the resilience of healthcare systems. However advanced genetic detection becomes, the defining question in antimicrobial resistance remains the same. For the patient at 2am, what matters is not genetic potential but biological reality. 

When pathogen meets antibiotic, what matters is growth. 

To explore how CPI can support the development and deployment of rapid phenotypic AST and next-generation AMR diagnostics, get in touch.